The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference

Thursday, May 10, 2012

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference09:30 EDT Thursday, May 10, 2012TARRYTOWN, N.Y., May 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012.  The presentation is scheduled for 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time).  The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.  Peter DworkinInvestor Relations Corporate Communications                       914-847-5126  914-847-7640                       manisha.narasimhan@regeneron.com  peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.